A 67-year-old woman, a visitor from South Africa, was referred to the emergency department of the Prince of Wales Hospital for the evaluation and management of lower abdominal pain and constipation of seven days duration. Her local led to her developing loose stools. Her past medical history was unremarkable other than for the presence tract infections (UTI). Her last UTI had occurred in March 2006.
500 mg) but became hypotensive, requiring intermittent boluses of metaraminol. No pathology was found at laparotomy and she was transferred to intensive care for the management of her hypotension. Her serum procalcitonin level checked on admission to intensive care unit was 22.3 ng/ml (normal range <0.5 ng/ml) suggesting an established bacteraemia. Given her previous history, severe urosepsis was suspected and she was commenced on empirical broad spectrum antimicrobial therapy (meropenem and vancomycin) commensurate with her severity of illness. Haemodynamic monitoring of cardiac output, preload (intrathoracic blood volume) and lung water was initiated using a PiCCO system (Pulsion Medical System AG, Munich, Germany). Guided by measurements of intrathoracic blood volume, the patient was resuscitated with nine litres 24 hours of intensive care unit (ICU) admission. She also required increasing doses of vasoconstrictors (noradrenaline and vasopressin) and inotropic support (dobutamine) to maintain an adequate was initiated early as she remained oligo-anuric with a persisting acidosis and worsening blood lactate /l), with an increasing procalcitonin (56.7 ng/ml) and C-reactive protein (149 mg/ml) levels, an activated protein C infusion was started at 24 μg/kg/hour. At this time all cultures were negative. The urinary pneumococcal antigen was reported as positive, suggesting invasive streptococcal sepsis. Meropenem and vancomycin were discontinued and she was treated with spontaneous diuresis and the renal support was discharged to the ward. . Levosimendan vascular resistance; its use has been predominantly Although levosimendan is not one of the inotropes recommended in the management of sepsis 7, 8 , its ignored in patients with severe septic hypodynamic shock. Furthermore successful use of levosimendan in animal models with severe septic shock has been reported 9 . There are very few case reports of using levosimendan in humans with severe septic hypodynamic shock 3, 4 . Currently a randomised, The metabolite OR 1896 reaches peak concentration two days after termination of the drug.
Because of long half-life, the effects of the drug last up to 7-9 days after discontinuation of the drug. levosimendan being used in Australia for a patient with severe septic shock. In earlier case reports 3, 4 of the use of levosimendan in septic shock, pulmonary artery catheterisation has been used to monitor the systemic haemodynamic changes. We used PiCCO monitoring to guide therapy in our patient and hence were unable to calculate the shunt fraction that may have increased following the initiation of the infusion in our patient might be a worsening of V:Q mismatch secondary to pulmonary vasodilatation.
CONCLUSION
Limited evidence to date suggests that there may be a role for the use of levosimendan in patients with severe septic hypodynamic shock.
